Parichay Infrastructure Limited has submitted a disclosure to BSE Limited regarding a substantial acquisition of shares in Biogen Pharmachem Industries Limited . The acquisition was made under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The transaction involved the purchase of 3,99,32,000 equity shares carrying voting rights. This quantity represents 4.42% of the target company's total share capital and total diluted share capital. The mode of acquisition was reported as the open market, with the transaction settling on May 18, 2026.

Holding Details

Prior to this acquisition, Parichay Infrastructure held 8,20,00,000 shares, which accounted for 9.08% of the total share capital. The recent purchase has altered the acquirer's position in the company. The disclosure confirms that the acquirer does not belong to the promoter or promoter group of the target entity.

Post-Acquisition Status

Following the acquisition of shares on May 18, 2026, the total shareholding of Parichay Infrastructure in Biogen Pharmachem Industries Limited has adjusted to 4,20,68,000 shares. This revised holding constitutes 4.66% of the total voting capital of the target company. The equity share capital of Biogen Pharmachem Industries Limited remains at Rs. 90,26,03,000, divided into 90,26,03,000 equity shares of Rs. 2 each.

The following table summarizes the shareholding changes:

The acquirer has confirmed that there are no shares held in the nature of encumbrance, nor are there any warrants or convertible securities that entitle the acquirer to receive additional voting rights.

Biogen Pharmachem Industries Limited has completed the allotment of bonus equity shares, with the process finalised on 18.05.2026. The allotment was carried out under Regulation 30, underscoring the company's adherence to regulatory disclosure norms governing corporate actions.

Bonus Share Allotment Details

The company has issued a substantial number of bonus equity shares to its shareholders as part of this corporate action. The key details of the allotment are summarised below:

Regulatory Compliance

The allotment of 15,04,33,833 bonus equity shares was completed in compliance with Regulation 30, which mandates timely disclosure of material corporate events to stock exchanges. Biogen Pharmachem Industries Limited fulfilled its disclosure obligations by reporting the completion of this bonus share allotment as required under the applicable regulatory framework.